Carcinoma, Large Cell News

Carcinoma, Large Cell	Welcome, Profile Billing Logout

||||||||||  carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion, Enrollment change, Combination therapy, Metastases:  ABOUND 70+: Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (clinicaltrials.gov) -  Sep 11, 2017
P4, N=143, Completed,  Sponsor: Celgene
Active, not recruiting --> Completed | N=280 --> 143

||||||||||  carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment closed, Combination therapy, Metastases:  ABOUND 70+: Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (clinicaltrials.gov) -  Oct 26, 2016
P4, N=280, Active, not recruiting,  Sponsor: Celgene Corporation
Active, not recruiting --> Completed | N=280 --> 143 Recruiting --> Active, not recruiting

|||||||||| Enrollment change, Trial termination, Trial primary completion date: Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) (clinicaltrials.gov) - Oct 7, 2016
P2, N=21, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=100 --> 21 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Oct 2016; Low Accrual

||||||||||  Alunbrig (brigatinib) / Takeda
New trial, Metastases:  An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) -  May 26, 2016
P=N/A, N=0, Available,  Sponsor: Ariad Pharmaceuticals

||||||||||  carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial primary completion date, Combination therapy, Metastases:  ABOUND 70+: Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (clinicaltrials.gov) -  Apr 21, 2016
P4, N=280, Recruiting,  Sponsor: Celgene Corporation
N=100 --> 21 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Oct 2016; Low Accrual Trial primary completion date: Dec 2016 --> Jul 2017

|||||||||| Enrollment closed: Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) (clinicaltrials.gov) - Sep 3, 2015
P2, N=100, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2016 --> Jul 2017 Recruiting --> Active, not recruiting

|||||||||| Trial primary completion date: Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) (clinicaltrials.gov) - Jun 11, 2015
P2, N=120, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Aug 2017

||||||||||  carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases:  RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation (clinicaltrials.gov) -  Apr 16, 2015
P4, N=49, Completed,  Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2016 --> Aug 2017 Active, not recruiting --> Completed

||||||||||  carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed, Metastases:  RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation (clinicaltrials.gov) -  Mar 2, 2015
P4, N=49, Active, not recruiting,  Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Caprelsa (vandetanib) / Sanofi
Trial completion, Metastases:  ZD6474 (ZACTIMA (clinicaltrials.gov) -  Jan 22, 2015
P3, N=1168, Completed,  Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment open, Combination therapy, Metastases:  ABOUND 70+: Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (clinicaltrials.gov) -  Jun 12, 2014
P4, N=284, Recruiting,  Sponsor: Celgene Corporation
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P4 trial, Combination therapy, Metastases:  ABOUND 70+: Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (clinicaltrials.gov) -  May 28, 2014
P4, N=284, Not yet recruiting,  Sponsor: Celgene Corporation

||||||||||  retaspimycin (IPI-504) / Infinity Pharma
Trial primary completion date:  A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) -  May 15, 2014
P2, N=226, Completed,  Sponsor: Infinity Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2014 --> Mar 2014

||||||||||  retaspimycin (IPI-504) / Infinity Pharma
Trial completion:  A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) -  May 15, 2014
P2, N=226, Completed,  Sponsor: Infinity Pharmaceuticals, Inc.
Trial primary completion date: Apr 2014 --> Mar 2014 Active, not recruiting --> Completed

||||||||||  Caprelsa (vandetanib) / Sanofi
Trial completion date, Metastases:  ZD6474 (ZACTIMA (clinicaltrials.gov) -  Apr 16, 2014
P3, N=1168, Active, not recruiting,  Sponsor: AstraZeneca
Active, not recruiting --> Completed Trial completion date: Sep 2012 --> Mar 2015

||||||||||  Caprelsa (vandetanib) / Sanofi
Enrollment change, Metastases:  ZD6474 (ZACTIMA (clinicaltrials.gov) -  Apr 16, 2014
P3, N=1168, Active, not recruiting,  Sponsor: AstraZeneca
Trial completion date: Sep 2012 --> Mar 2015 N=924 --> 1168

||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
Trial completion, Combination therapy:  A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) -  Feb 22, 2014
P1, N=36, Completed,  Sponsor: Pharmacyclics
N=924 --> 1168 No longer recruiting --> Completed

||||||||||  Foscan (temoporfin) / ABVC BioPharma
Trial withdrawal:  Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer (clinicaltrials.gov) -  Jan 13, 2014
P1, N=0, Withdrawn,  Sponsor: University of Arkansas
No longer recruiting --> Completed Recruiting --> Withdrawn

||||||||||  Foscan (temoporfin) / ABVC BioPharma
Enrollment change:  Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer (clinicaltrials.gov) -  Jan 13, 2014
P1, N=0, Withdrawn,  Sponsor: University of Arkansas
Recruiting --> Withdrawn N=10 --> 0

||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
Trial termination:  Trial of Motexafin Gadolinium and Pemetrexed (Alimta (clinicaltrials.gov) -  Oct 23, 2013
P2, N=74, Terminated,  Sponsor: Pharmacyclics
N=10 --> 0 Completed --> Terminated

||||||||||  carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Metastases:  RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation (clinicaltrials.gov) -  Jan 15, 2013
P4, N=47, Recruiting,  Sponsor: Novartis Pharmaceuticals
Completed --> Terminated N=85 --> 47

||||||||||  retaspimycin (IPI-504) / Infinity Pharma
Enrollment closed:  A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Nov 11, 2012
P2, N=226, Active, not recruiting,  Sponsor: Infinity Pharmaceuticals, Inc.
N=85 --> 47 Recruiting --> Active, not recruiting

|||||||||| Enrollment open: Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) (clinicaltrials.gov) - Sep 4, 2012
P2, N=120, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting

||||||||||  Foscan (temoporfin) / ABVC BioPharma
New P1 trial:  Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer (clinicaltrials.gov) -  Jul 9, 2012
P1, N=0, Withdrawn,  Sponsor: University of Arkansas

||||||||||  temozolomide / Generic mfg.
Trial termination:  Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) (clinicaltrials.gov) -  Feb 22, 2012
P2, N=53, Terminated,  Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Completed --> Terminated

|||||||||| New P2 trial: Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) (clinicaltrials.gov) - Jan 16, 2012
P2, N=120, Recruiting, Sponsor: M.D. Anderson Cancer Center

||||||||||  carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment open, Metastases:  RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation (clinicaltrials.gov) -  Nov 29, 2011
P4, N=47, Recruiting,  Sponsor: Novartis Pharmaceuticals
Completed --> Terminated Not yet recruiting --> Recruiting



	Diseases Companies Products Productz Mechanisms of Action Sites